好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

CSF Inflammatory and Vasoactive Mediators Associated with Poor Functional Outcome in Subarachnoid Hemorrhage (SAH) Patients.
Cerebrovascular Disease and Interventional Neurology
S15 - Intracerebral Hemorrhage and SAH (1:33 PM-1:44 PM)
004
Recent evidence suggest that inflammation may play an important role in the pathogenesis of vasospasm and delayed cerebral ischemia (DCI) following SAH. We aimed to explore a panel of cytokines and vasoactive mediators in CSF of SAH patients to identify candidate inflammatory biomarkers.

To study the association of CSF inflammatory and vasoactive mediators with poor functional outcome in subarachnoid hemorrhage (SAH).


CSF samples were collected through an external ventricular drain (EVD) in a prospective SAH cohort (N= 67). We evaluated modified Rankin Scale (mRS) score at 3-month intervals and assessed the occurrence of vasospasm. Poor functional outcome was defined as mRS >2. Angiographic vasospasm was defined as >50% reduction in the caliber of any vessel on post-SAH day 7 cerebral angiogram. We compared the CSF profile of 28 cytokines (Human Magnetic Luminex Assay, R&D systems) in post-SAH day 1, 3 and 5 by outcome. Continuous variables were compared with Student’s t or Wilcoxon rank sum test depending on data distribution.

In the SAH cohort (mean age 55.1, 69% female), 67% had a Hunts and Hess ≥3 and 89% had a modified Fischer scale of ≥3. 48% had poor 3-month outcome and 36% had poor 6-month outcome. Out of the 28 cytokines, 3 were below measurement range and were excluded from analysis: CCL11/Eotaxin, IL10 and IL5. The top 3 markers showing strongest association with outcome were CSF VEGFR1 (p=0.0014), IL12p70 (p=0.0023) and CCL5/RANTES (p=0.0038).


These study results suggest a possible association between elevated VEGFR1 and poor functional outcome following SAH. Further targeted studies are necessary to investigate the role of CSF VEGFR1, IL12p70 and CCL5/RANTES and SAH outcome.
Authors/Disclosures
Aisha R. Saand, MD (UPMC)
PRESENTER
No disclosure on file
Fang Yu, Jr., MD (University of Pittsburgh) No disclosure on file
Jong W. Lee, MD, PhD (Brigham and Women's Hospital) The institution of Dr. Lee has received research support from NIH. The institution of Dr. Lee has received research support from NIH. The institution of Dr. Lee has received research support from UCB. Dr. Lee has received personal compensation in the range of $10,000-$49,999 for serving as a Contract work with Teladoc.
No disclosure on file
MingMing Ning, MD (Mass General Hospital/Harvard Medical School) No disclosure on file
Eng Lo, MD (Massachusetts General Hospital) Eng Lo, MD has nothing to disclose.
Sherry Hsiang-Yi Chou, MD (Departmnt of Neurology, Northwestern Feinberg School of Medicine) Dr. Chou has received personal compensation in the range of $500-$4,999 for serving as a Consultant for CSL-Behring. Dr. Chou has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for CSL-Behring. The institution of Dr. Chou has received research support from NIH/NINDS. The institution of Dr. Chou has received research support from University of Pittsburgh.